40.79
전일 마감가:
$42.06
열려 있는:
$41.8
하루 거래량:
1.11M
Relative Volume:
1.10
시가총액:
$2.17B
수익:
$238.11M
순이익/손실:
$-31.45M
주가수익비율:
-64.40
EPS:
-0.6334
순현금흐름:
$7.66M
1주 성능:
-4.32%
1개월 성능:
+27.63%
6개월 성능:
+66.76%
1년 성능:
+258.91%
Axogen Inc Stock (AXGN) Company Profile
명칭
Axogen Inc
전화
(386) 462-6817
주소
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
AXGN
Axogen Inc
|
40.79 | 2.24B | 238.11M | -31.45M | 7.66M | -0.6334 |
|
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | Wells Fargo | Overweight |
| 2025-12-01 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Lake Street | Buy |
| 2024-07-01 | 개시 | Raymond James | Outperform |
| 2022-11-11 | 재개 | Jefferies | Buy |
| 2022-05-09 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | Guggenheim | Buy |
| 2020-06-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-05-07 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | 개시 | Canaccord Genuity | Buy |
| 2018-03-02 | 재확인 | Lake Street | Buy |
| 2018-01-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2017-11-30 | 개시 | Jefferies | Buy |
| 2017-11-21 | 재확인 | Lake Street | Buy |
| 2017-07-31 | 개시 | Leerink Partners | Outperform |
| 2017-06-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-06 | 개시 | ROTH Capital | Buy |
| 2016-11-22 | 업그레이드 | Lake Street | Hold → Buy |
| 2016-11-07 | 재확인 | Wedbush | Outperform |
| 2016-11-03 | 다운그레이드 | Lake Street | Buy → Hold |
| 2016-08-04 | 재확인 | Wedbush | Outperform |
| 2014-05-14 | 개시 | Dawson James | Buy |
| 2013-10-31 | 재확인 | Ladenburg Thalmann | Buy |
모두보기
Axogen Inc 주식(AXGN)의 최신 뉴스
Technical Reactions to AXGN Trends in Macro Strategies - Stock Traders Daily
Insider Sell Alert: Jens Kemp Sells 4,000 Shares of Axogen Inc (AXGN) - GuruFocus
Axogen CMO Jens Kemp sells $173,761 in company stock By Investing.com - Investing.com Nigeria
Axogen CFO Lindsey Hartley sells $45,897 in AXGN stock By Investing.com - Investing.com Nigeria
Axogen CFO Lindsey Hartley sells $45,897 in AXGN stock - Investing.com UK
[144] Axogen, Inc. SEC Filing - Stock Titan
Axogen Director Sold Shares Worth Over $720K - TradingView
Axogen (AXGN) director exercises options and sells 11,050 common shares - Stock Titan
[Form 4] Axogen, Inc. Insider Trading Activity - Stock Titan
Axogen (AXGN) CMO sells 4,000 shares around $43 per share - Stock Titan
Axogen (NASDAQ: AXGN) CFO nets shares after option exercises and sales - Stock Titan
Axogen (AXGN) Sales VP sells 3,878 shares, retains 92,416 - Stock Titan
Axogen (NASDAQ: AXGN) VP Quackenbush discloses initial equity holdings - Stock Titan
AxoGen, Inc. (AXGN) Stock Analysis: 17% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
AXGN (NASDAQ) Form 144 lists 3,878 shares via Morgan Stanley broker - Stock Titan
First Light, Mathew Arens report 3.62M Axogen holdings (AXGN) - Stock Titan
How many employees work at AxoGen? - Revelio Labs
Number of shareholders of Axogen, Inc. – NASDAQ:AXGN - TradingView
Axogen outlines at least $270M 2026 revenue on at least 20% growth amid Avance biologic channel transition - MSN
Canaccord Genuity Sticks to Its Buy Rating for AxoGen (AXGN) - The Globe and Mail
Axogen (AXGN) Is Up 10.3% After Raising 2026 Revenue Outlook Despite Wider Q1 Loss – Has The Bull Case Changed? - simplywall.st
Axogen (AXGN) Q1 2025 Earnings Transcript - AOL.com
AxoGen (NASDAQ:AXGN) Cut to "Hold" at Wall Street Zen - MarketBeat
Axogen, Inc. (NASDAQ:AXGN) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
Axogen, Inc. (NASDAQ:AXGN) Analysts Are Pretty Bullish On The Stock After Recent Results - Yahoo Finance
Axogen (AXGN) Q1 2026 Deep Dive: $0.07 EPS, Revenue Up 27% - AlphaStreet
Nerve Repair And Regenerative Market Set to Boom Rapidly, - openPR.com
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference - The Manila Times
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78 - simplywall.st
AxoGen Reports Third Quarter 2025 Financial Results and Growth - HarianBasis.co
A Quick Look at Today's Ratings for AxoGen(AXGN.US), With a Forecast Between $48 to $55 - Moomoo
AXGN Maintained by Canaccord Genuity -- Price Target Raised to $50 - GuruFocus
Vanguard reports 2.66M Axogen stake (NASDAQ: AXGN) - Stock Titan
[ARS] Axogen, Inc. SEC Filing - Stock Titan
FDA win and 20% growth frame Axogen (NASDAQ: AXGN) 2026 pay vote - Stock Titan
AXGN Maintained by Citizens -- Price Target Raised to $50.00 - GuruFocus
AxoGen (NASDAQ:AXGN) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
AXGN Maintained by Wells Fargo -- Price Target Raised to $38.00 - GuruFocus
AxoGen (NASDAQ:AXGN) Price Target Raised to $48.00 at Wells Fargo & Company - MarketBeat
Axogen Q1 2026 revenue up 26.6% to USD 61.5M - Medical Buyer
Citizens raises AxoGen stock price target to $50 on strong sales - Investing.com Australia
AXGN Maintained by HC Wainwright & Co. -- Price Target Raised to $50 - GuruFocus
H.C. Wainwright raises AxoGen stock price target to $50 on revenue beat - Investing.com Nigeria
H.C. Wainwright raises AxoGen stock price target to $50 on revenue beat By Investing.com - Investing.com South Africa
Mizuho raises AxoGen stock price target to $55 on strong growth By Investing.com - Investing.com South Africa
AxoGen Delivers Strong Q1 Growth and Raises 2026 Outlook - The Globe and Mail
Mizuho raises AxoGen stock price target to $55 on strong growth - Investing.com Australia
AxoGen (NASDAQ:AXGN) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Axogen Inc (AXGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):